Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shimadzu Corporation (7701.T)
Kyoto, JP
Shimadzu Corporation, founded in Kyoto, Japan, in 1875, is a global entity specializing in the development, production, and distribution of a diverse range of advanced instruments and systems. The company's extensive offerings span analytical and measuring instruments, medical systems, industrial machinery, and aviation equipment. Its analytical instrumentation segment provides comprehensive solutions including gas and liquid chromatography, gas and liquid chromatograph-mass spectrometry, molecular and elemental spectroscopy, and surface analysis. This division also manufactures life science laboratory instruments, total organic carbon analyzers, continuous monitoring analysis systems, thermal and particle size analysis equipment, materials testing and inspection devices, non-destructive testing apparatus, and precision balances, all supported by data management software. In the medical sector, Shimadzu delivers cutting-edge imaging technologies such as angiography, fluoroscopy, mobile C-arms, radiography and mobile X-ray systems, and fluorescence imaging products. The company further produces high-precision optical components, including diffraction gratings, aspherical mirrors, specialized laser mirrors and windows for high-power applications, polka-dot beam splitters, and accurate refractometers. For industrial use, Shimadzu offers machinery ranging from turbo molecular pumps, helium leak detectors, sputtering and multi-deposition systems, and vacuum heat-treatment furnaces. Their industrial portfolio also includes liquid delivery gear pumps, mechatronic systems like glass fiber winders and liquid crystal injection systems, and dynamic balancing machines, alongside hydraulic equipment such as hydraulic gear pumps, power packages, and multi-control valves. Additionally, the company supplies the aerospace industry with essential components including electro-mechanical actuators, advanced flight control systems, and landing gear systems.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.06% | -7.66% | -8.43% | -15.82% | -19.48% | -16.88% | -2.62% | -19.45% | -6.52% | +99.09% | +812.79% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 7 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Hardware, Equipment & Parts: +10.0%+4.0% Q1'26: +4.7% (vs Q1'25)
-
EPS growth Hardware, Equipment & Parts: +20.2%+14.1% Q1'26: +21.4% (vs Q1'25)
-
FCF margin FCF growth · Hardware, Equipment & Parts: +27.1%+5.5% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Hardware, Equipment & Parts: +8.7%+13.1% ★ Q1'26: +14.5% (vs Q1'25)
-
ROIC Hardware, Equipment & Parts: +5.7%+13.4% ★ Q1'26: +17.3% (vs Q1'25)
-
Share dilution Hardware, Equipment & Parts: +0.0%-1.4% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Hardware, Equipment & Parts: -0.70×0.11× ★ Q1'26: 0.09× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 12 Rev. Ana. 12 EPS Ana. |
Mar 2027 4 Rev. Ana. 2 EPS Ana. |
Mar 2028 11 Rev. Ana. 11 EPS Ana. |
Mar 2029 4 Rev. Ana. 4 EPS Ana. |
Mar 2030 3 Rev. Ana. 2 EPS Ana. |
Mar 2031 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
314.70B
est: 315.05B (-0.1%)
|
342.24B
est: 342.17B (+0.0%)
|
342.48B
est: 338.32B (+1.2%)
|
376.53B
est: 375.22B (+0.3%)
|
391.21B
est: 391.87B (-0.2%)
|
385.44B
est: 392.03B (-1.7%)
|
393.50B
est: 382.58B (+2.9%)
|
428.18B
est: 427.02B (+0.3%)
|
482.24B
est: 472.12B (+2.1%)
|
511.90B
est: 519.63B (-1.5%)
|
539.05B
est: 538.65B (+0.1%)
|
555.30B
544.20B – 559.42B
+3.1% YoY
|
596.40B
586.75B – 602.92B
+7.4% YoY
|
624.52B
584.20B – 656.98B
+4.7% YoY
|
667.92B
664.69B – 671.15B
+6.9% YoY
|
716.26B
686.88B – 739.19B
+7.2% YoY
|
780.13B
748.13B – 805.10B
+8.9% YoY
|
| EBITDA |
35.18B
est: 56.84B (-38.1%)
|
45.14B
est: 61.74B (-26.9%)
|
46.67B
est: 61.04B (-23.5%)
|
53.46B
est: 67.70B (-21.0%)
|
56.12B
est: 70.70B (-20.6%)
|
55.26B
est: 70.73B (-21.9%)
|
65.48B
est: 69.03B (-5.1%)
|
80.23B
est: 77.04B (+4.1%)
|
86.13B
est: 85.18B (+1.1%)
|
91.86B
est: 89.58B (+2.5%)
|
92.40B
est: 92.86B (-0.5%)
|
95.73B
93.81B – 96.44B
+3.1% YoY
|
102.81B
101.15B – 103.94B
+7.4% YoY
|
107.66B
100.71B – 113.26B
+4.7% YoY
|
115.14B
114.59B – 115.70B
+6.9% YoY
|
123.48B
118.41B – 127.43B
+7.2% YoY
|
134.49B
128.97B – 138.79B
+8.9% YoY
|
| EBIT |
27.19B
est: 44.96B (-39.5%)
|
35.70B
est: 48.83B (-26.9%)
|
37.09B
est: 48.28B (-23.2%)
|
42.82B
est: 53.54B (-20.0%)
|
44.48B
est: 55.92B (-20.5%)
|
41.85B
est: 55.94B (-25.2%)
|
49.74B
est: 54.59B (-8.9%)
|
63.81B
est: 60.93B (+4.7%)
|
68.22B
est: 67.37B (+1.3%)
|
72.75B
est: 70.75B (+2.8%)
|
71.72B
est: 73.34B (-2.2%)
|
75.61B
74.10B – 76.17B
+3.1% YoY
|
81.21B
79.89B – 82.09B
+7.4% YoY
|
85.04B
79.55B – 89.46B
+4.7% YoY
|
90.95B
90.51B – 91.39B
+6.9% YoY
|
97.53B
93.53B – 100.65B
+7.2% YoY
|
106.22B
101.87B – 109.62B
+8.9% YoY
|
| Net Income |
18.45B
est: 16.93B (+9.0%)
|
23.90B
est: 23.96B (-0.2%)
|
26.47B
est: 24.59B (+7.7%)
|
29.84B
est: 29.47B (+1.3%)
|
32.52B
est: 32.59B (-0.2%)
|
31.77B
est: 32.18B (-1.3%)
|
36.10B
est: 32.91B (+9.7%)
|
47.29B
est: 44.77B (+5.6%)
|
52.05B
est: 50.10B (+3.9%)
|
57.04B
est: 55.92B (+2.0%)
|
53.78B
est: 55.99B (-4.0%)
|
54.82B
50.86B – 57.76B
-2.1% YoY
|
59.60B
59.56B – 59.63B
+8.7% YoY
|
64.44B
57.45B – 76.37B
+8.1% YoY
|
73.94B
71.41B – 76.47B
+14.8% YoY
|
84.05B
79.56B – 87.54B
+13.7% YoY
|
101.81B
96.38B – 106.05B
+21.1% YoY
|
| SGA |
90.05B
est: 82.44B (+9.2%)
|
95.25B
est: 89.54B (+6.4%)
|
90.02B
est: 88.53B (+1.7%)
|
97.34B
est: 98.19B (-0.9%)
|
102.55B
est: 102.54B (+0.0%)
|
99.95B
est: 102.58B (-2.6%)
|
96.30B
est: 100.11B (-3.8%)
|
104.53B
est: 111.74B (-6.5%)
|
121.71B
est: 123.54B (-1.5%)
|
135.79B
est: 132.46B (+2.5%)
|
144.50B
est: 137.31B (+5.2%)
|
141.55B
138.72B – 142.60B
+3.1% YoY
|
152.03B
149.57B – 153.69B
+7.4% YoY
|
159.20B
148.92B – 167.47B
+4.7% YoY
|
170.26B
169.44B – 171.08B
+6.9% YoY
|
182.58B
175.09B – 188.43B
+7.2% YoY
|
198.86B
190.71B – 205.23B
+8.9% YoY
|
| EPS |
62.55
est: 57.77 (+8.3%)
|
81.05
est: 81.77 (-0.9%)
|
89.79
est: 83.92 (+7.0%)
|
101.26
est: 100.57 (+0.7%)
|
110.41
est: 111.25 (-0.8%)
|
107.84
est: 109.84 (-1.8%)
|
122.52
est: 112.32 (+9.1%)
|
160.49
est: 152.79 (+5.0%)
|
176.63
est: 171.94 (+2.7%)
|
193.54
est: 189.75 (+2.0%)
|
183.55
est: 192.24 (-4.5%)
|
187.92
173.59 – 197.16
-2.2% YoY
|
203.41
203.30 – 203.52
+8.2% YoY
|
218.62
196.08 – 260.66
+7.5% YoY
|
249.85
243.74 – 261.02
+14.3% YoY
|
286.87
271.57 – 298.80
+14.8% YoY
|
347.50
328.97 – 361.96
+21.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 4/5 | 4/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 3/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.85% | 9.67M | 0.40% |
| 2 | American Century Quality Diversified International ETF QINT | 0.57% | 3.71M | 0.40% |
| 3 | iShares MSCI Japan Small Cap UCITS ETF IDJP.L | 0.44% | 2.47M | 0.58% |
| 4 | iShares MSCI Japan Small-Cap ETF SCJ | 0.43% | 1.11M | 0.50% |
| 5 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.16% | 373.6K | 0.83% |
| 6 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.16% | 22.51M | 0.40% |
| 7 | TD Global Healthcare Leaders Index ETF TDOC.TO | 0.15% | 137.9K | 0.39% |
| 8 | Invesco JPX-Nikkei 400 UCITS ETF N4US.L | 0.14% | 288.7K | 0.19% |
| 9 | Invesco JPX-Nikkei 400 UCITS ETF N400.L | 0.14% | 288.1K | 0.19% |
| 10 | Invesco JPX-Nikkei 400 UCITS ETF NS4E.DE | 0.14% | 287.9K | 0.19% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yasunori Yamamoto | President, Chief Executive Officer & Representative Director | 118M | male |
| Hidezo Maruyama | Senior Managing Executive Officer of Risk Management, Environmental Management & Director | — | male |
| Katsuaki Kaito | Senior Managing Executive Officer | — | — |
| Koki Aoyama | Senior Managing Executive Officer | — | — |
| Komei Arakane | Managing Executive Officer & Chief Financial Officer | — | — |
| Masaki Ono | Manager of Investor Relations Group & Corporate Communications Department | — | — |
| Shigenori Aoyama | Senior Managing Executive Officer & Chief HR Officer | — | — |
| Shunei Matoba | Managing Executive Officer | — | — |
| Takahiro Nishimoto | Managing Executive Officer & Chief Technology Officer | — | — |
| Teruyuki Oyagi | Senior Manager of Investor Relations Group | — | male |
| Yoshiaki Maeda | Managing Executive Officer | — | — |
| Akira Watanabe | Senior Managing Executive Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7701.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
